InvestorsHub Logo
Followers 0
Posts 85
Boards Moderated 0
Alias Born 09/12/2001

Re: None

Tuesday, 12/15/2020 4:00:31 PM

Tuesday, December 15, 2020 4:00:31 PM

Post# of 1106
12/04/20: Cowen analyst John Scott reiterated an Outperform rating and on Immunogen Inc. (NASDAQ: IMGN) and highlighted the company as his Best Biotech Idea for 2021. What the street appears to be missing is the de-risked first-in-class potential of lead drugmirvetuximab.

The analyst stated "We expect top-line SORAYA data in 3Q21, BLA submission before YE21, and accelerated approval in 1H22. We estimate a >$1.2B commercial opp w/ peak US sales of$900MM. Assuming a 3-4x multiple of comm opp suggests value of $4B+, making IMGN anattractive potential M&A target (market cap $1.05B)"

https://www.streetinsider.com/Analyst+Comments/Immunogen+Inc.+(IMGN)+Names+Top+Biotech+Idea+for+2021+at+Cowen/17682898.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMGN News